The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Auvelity
dextromethorphan hydrobromide, bupropion hydrochloride · DEXTROMETHORPHAN HYDROBROMIDE 30 mg/1; BUPROPION HYDROCHLORIDE 105 mg/1 · Tablet, Multilayer, Extended Release · Oral · Axsome Therapeutics, Inc.
NDC 81968-0030-22 · 1 BOTTLE in 1 CARTON / 21 TABLET, MULTILAYER, EXTENDED RELEASE in 1 BOTTLE · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for dextromethorphan hydrobromide, bupropion hydrochloride (oral solid) in the next 90 days
sole-source market · price up 6% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,054.69 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA215430
- TE code
- —
- Approval date
- Aug 18, 2022
- Patents / exclusivity
- 204 patents, 2 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | I-913 | Apr 30, 2029 |
| exclusivity | I-913 | Apr 30, 2029 |
| patent | 12653795 | Nov 28, 2043 |
| patent | 12194036 | Apr 20, 2043 |
| patent | 11844797 | Apr 20, 2043 |
| patent | 11839612 | Mar 2, 2043 |
| patent | 12042473 | Feb 23, 2043 |
| patent | 12146889 | Feb 23, 2043 |
| patent | 11752144 | Feb 23, 2043 |
| patent | 12472155 | Feb 23, 2043 |
| patent | 11986444 | Feb 15, 2043 |
| patent | 12370154 | Feb 15, 2043 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of dextromethorphan hydrobromide, bupropion hydrochloride (Tablet, Multilayer, Extended Release)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Axsome Therapeutics, Inc. | DEXTROMETHORPHAN HYDROBROMIDE 30 mg/1; BUPROPION HYDROCHLORIDE 105 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Axsome Therapeutics, Inc. | DEXTROMETHORPHAN HYDROBROMIDE 45 mg/1; BUPROPION HYDROCHLORIDE 105 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Axsome Therapeutics, Inc. | DEXTROMETHORPHAN HYDROBROMIDE 105 mg/1; BUPROPION HYDROCHLORIDE 30 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Axsome Therapeutics, Inc. | DEXTROMETHORPHAN HYDROBROMIDE 105 mg/1; BUPROPION HYDROCHLORIDE 45 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Axsome Therapeutics, Inc. | BUPROPION HYDROCHLORIDE 105 mg/1; DEXTROMETHORPHAN HYDROBROMIDE 30 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Axsome Therapeutics, Inc. | BUPROPION HYDROCHLORIDE 105 mg/1; DEXTROMETHORPHAN HYDROBROMIDE 45 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Auvelity — NDC 81968-0030-22," retrieved September 3, 2026, https://drugdashboards.com/drug/81968003022.
Free to cite with attribution — see how the data is put together.